pocketful logo
Mercury Laboratories Ltd logo

Mercury Laboratories Ltd

NSE: BSE: 538964

805.15

(2.25)%

Tue, 10 Feb 2026, 11:51 pm

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    96.62

  • Net Profit

    3.14

  • P/B

    1.83

  • Sector P/E

    40.03

  • P/E

    31.25

  • EV/EBITDA

    12.55

  • Debt/Equity (Industry)

    0.24

  • Interest Cover (Industry)

    12.78

  • ROCE (Industry)

    15.36

  • RONW (Industry)

    13.46

  • ROE

    6.01

  • ROCE

    8.98

  • Debt/Equity

    0.11

  • EPS (TTM)

    40.95

  • Dividend Yield

    0.43

  • Book Value

    464.65

  • Interest Cover

    9.47

Analysis

all

thumbs up icon

Pros

  • Dividends paid are thoroughly covered by earnings (13.5x coverage).
  • Mercury Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Mercury Laboratories is profitable, therefore cash runway is not a concern.
  • Mercury Laboratories is profitable, therefore cash runway is not a concern.
  • Debt is well covered by operating cash flow (86.8%, greater than 20% of total debt).
thumbs up icon

Cons

  • Dividend payments have increased, but Mercury Laboratories only paid a dividend in the past 5 years.
  • Whilst dividend payments have been stable, Mercury Laboratories has been paying a dividend for less than 10 years.
  • Mercury Laboratories's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Mercury Laboratories's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • High level of physical assets or inventory.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters73.6673.6673.6673.6673.66
FII00000
DII00000
Public26.3426.3426.3426.3426.34
Government00000

Read More

Technical Analysis

RSI

50.03

MACD

-9.56

50 DMA

823.45

200 DMA

843.10

Support and Resistance

TypeR1R2R3PPS1S2S3
Classic1012.55914.60857.30816.65759.35718.70620.75
Fibonacci914.60877.18854.07816.65779.23756.12718.70
Camarilla826.94817.96808.98816.65791.02782.04773.06

Pivots Level: Classic

R3

+195.90

1012.55

R2

+97.95

914.60

R1

+40.65

857.30

816.65
816.65
Pivot Point
LTP: 805.15

S1

-57.30

759.35

S2

-97.95

718.70

S3

-195.90

620.75

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    793.85

  • 20-EMA

    800.14

  • 30-EMA

    807.09

  • 50-EMA

    818.08

  • 100-EMA

    832.62

  • 200-EMA

    848.47

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
11 Feb 2026board-meetingsQuarterly Results
14 May 2025agm
14 May 2025dividend₹3.50 Dividend /Share06 Aug 2025
24 Jul 2024agm
28 May 2024dividend₹3.50 Dividend /Share21 Sept 2024
05 May 2023dividend₹3.50 Dividend /Share21 Sept 2023
05 May 2023agm
26 May 2022agm
26 May 2022dividend₹3.50 Dividend /Share21 Sept 2022
28 May 2021agm

Read More

Peer Comparison

Mercury Laboratories Ltd logo

Mercury Laboratories Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Cipla Ltd logo

Cipla Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Read More

About Mercury Laboratories Ltd

Mercury Laboratories is engaged into the manufacturing and export of wide range of Pharmaceutical items.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1982

Headquarters

CEO

SANJAY SHANTILAL PATEL

Employees

Contact

Website icon

Website

http://www.mercurylabs.com

Email icon

Email

secretarial@mercurylabs.com, mllbrd@mercurylabs.co

Phone icon

Phone

91-22-66372841

Location icon

Location

1st Floor 18 Shreeji Bhuwan 51, Princess Street Mangaladas Rd, Mumbai, Maharashtra, 400002

Read More

mercury laboratories ltd History

YearHistory
1982
  • The Company was incorporated as Mercury Laboratories Pvt. Limited.
1992
  • The Company became a Public Ltd. company
  • The company's name was changed to Mercury Laboratories Limited.
2015
  • Mercury Laboratories was listed in BSE.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
No Result Found

Read More

mercury laboratories limited News

Mercury Laboratories Assigns Additional VP Role to Chief Operating Officer

Mercury Laboratories Limited has assigned an additional role of Vice President-Marketing Sales to Saurabh Mittal, who serves as Chief Operating Officer, effective November 17, 2025. The appointment involves a senior management personnel with over 15 years of corporate experience in marketing, business development, and system processes across established and start-up organizations.

17 Nov 2025

corporate governance

Mercury Laboratories Delays New Injectable Plant Commissioning by 13 Months to December 2026

Mercury Laboratories has deferred the commissioning of its new Small Volume Parenteral (SVPs) manufacturing plant by 13 months from the originally scheduled November 2025 to December 2026. The plant, located at Jarod with a capacity to manufacture 75 million units annually, involves an estimated cost of INR 30 crores. The delay is attributed to revisions in Schedule M guidelines by the Ministry of Health and Family Welfare, which mandated additional compliance and infrastructural requirements for pharmaceutical manufacturing facilities. The company states there is no material adverse impact on overall business operations due to the delay and is taking necessary steps to expedite project completion.

12 Nov 2025

stock

Mercury Laboratories Reports 69% Jump in Quarterly Net Profit to Rs 164.33 Lakhs

Mercury Laboratories Limited announced its unaudited financial results for the quarter and half year ended September 30, 2025. The pharmaceutical company reported a net profit after tax of Rs 164.33 lakhs for the quarter, compared to Rs 96.76 lakhs in the previous quarter, representing a significant increase. Revenue from operations for the quarter stood at Rs 1,900.86 lakhs, up from Rs 1,813.54 lakhs in the previous quarter. For the half year period, net profit reached Rs 261.09 lakhs with revenue from operations at Rs 3,714.40 lakhs. The company's total comprehensive income for the quarter was Rs 164.00 lakhs. Basic earnings per share for the quarter was Rs 13.69 compared to Rs 8.06 in the previous quarter. The Board of Directors approved these results at their meeting held on November 11, 2025. The company operates in a single segment of pharmaceutical products and has paid-up equity share capital of Rs 120.00 lakhs with face value of Rs 10 per share.

12 Nov 2025

earnings

Mercury Laboratories Appoints Seema Salvi as Head of Injectable Production Department

Mercury Laboratories Limited appointed Ms. Seema Salvi as Head of the Injectable Production Department effective November 04, 2025. Salvi, aged 49, holds a Bachelor's degree in Pharmacy and brings over 26 years of experience in injection production. She was previously associated with Harson Laboratories India Pvt. Ltd. and Crescent Labs Pvt Ltd. The appointment is for full-time employment as part of the company's senior management personnel changes.

04 Nov 2025

corporate governance

Mercury Laboratories Shareholders Approve All Resolutions at 44th AGM Including ₹3.50 Dividend

Mercury Laboratories Limited held its 44th Annual General Meeting on August 13, 2025, via video conferencing with 1,405 shareholders on record. All nine resolutions were approved with overwhelming support, including adoption of audited financial statements for the year ended March 31, 2025, and declaration of ₹3.50 dividend per equity share of ₹10 each. Key appointments approved include re-appointment of Ms. Janki R Shah as Non-Executive Non-Independent Director, approval of her remuneration exceeding 50% of total non-executive director remuneration, re-appointment of Mr. Rajendra R Shah as Managing Director effective April 1, 2026, and appointment of Mr. Sanjay Patel as Independent Director. Shareholders also approved remuneration for Mr. Paresh Mistry as Non-Executive Director, ratified cost auditor remuneration for 2025-26, and appointed Dholakia & Associates LLP as secretarial auditors. The meeting saw participation from 41 shareholders (9 promoters, 32 public) through video conferencing, with voting conducted through remote e-voting and e-voting during the AGM.

14 Aug 2025

corporate action

Showing 15 of 6
Rows per page:

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800